Glaxo’s Advair May Face Larger Than Forecasted Generic Hit

Sales of GlaxoSmithKline’s (Glaxo) Advair may decline significantly if generic drugmakers Mylan, Sandoz and Vectura are able to convince U.S. regulators to approve a truely substitutable generic.

Generic manufacturers have gained approval for the drug, but not the delivery technology. Mylan is working on a substitutable Advair that includes both the inhalation technology in the device as well as the drug, making it a true generic.

Consensus revenue forecasts predict a 17 percent decline in sales from 2014 to 2017. Glaxo reported revenue of $8.1 billion from the respiratory drug in 2011, close to 18 percent of its total revenue.

Read more>>

Bloomberg BRIEF Newsletters